about
Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltrationNeuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours.Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours.Vascular patterns provide therapeutic targets in aggressive neuroblastic tumorsBiotensegrity of the extracellular matrix: physiology, dynamic mechanical balance, and implications in oncology and mechanotherapyQuantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma.A stiff extracellular matrix is associated with malignancy in peripheral neuroblastic tumors.Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort.Diagnostic implications of intrapatient genetic tumor heterogeneity.1p36 deletion results in a decrease in glycosaminoglycans which is associated with aggressiveness in neuroblastic tumors.Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.Lymph microvascularization as a prognostic indicator in neuroblastoma.Comparative study of MLPA-FISH to determine DNA copy number alterations in neuroblastic tumorsCirculating microRNA biomarkers for metastatic disease in neuroblastoma patientsGenetic features of neuroblastic tumors associated with opsoclonus-myoclonus syndrome opens up the possibility for detection in peripheral bloodHeterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma StudyExtra-Adrenal Adult Neuroblastoma With Aberrant Germ Cell Marker Expression: Maturation After Chemotherapy as an Important Clue to a Challenging Diagnosis
P50
Q34346730-B1A85AB9-4E75-496C-8222-1DB13EBE20EBQ34438553-318D6846-E004-45E1-8953-97B118B31087Q35677257-AD5AD3D2-984F-4103-8004-5BCE49595A6DQ35965396-E2C9F11E-CDC8-4F5E-A4F5-651045A5D971Q37190218-3DBA169D-BB48-4DAB-9A72-DECA8384C73AQ37614639-03AEBFC8-EAC4-4E1F-8132-5B9DB46916ECQ39064490-87AE95BB-3433-4743-8D42-15563323840CQ40437981-D1ED3D2D-8019-4C32-BCF8-2A5889B29C07Q40651848-A5886140-2E1D-41B5-94EB-92686E16767BQ42252770-5276BDAF-E423-465D-ABCA-751F4100545AQ49714713-058FB777-2890-4A9F-808E-8E57692063EDQ50853134-4568994F-6E9B-4E4D-8358-F2CE2EBD0EDDQ54977695-D932D2CF-9C0A-42C7-A022-5F920A3B31C4Q55241229-D921963C-1FF2-4DD7-BE15-1CCC5E7B0835Q57906744-25F61269-FADD-4A06-BD01-CEA49DDDE1E5Q60912823-F0F6C520-E00A-49E2-9105-C76D75CC575EQ87417322-0995F59C-B3D4-424E-96EA-F7B26E07BEF1Q88654128-5133027F-5038-46BA-B505-473D7C262D98Q92590034-53B507BE-B48A-4442-BE7E-26D4C5472003
P50
description
researcher ORCID ID = 0000-0002-8798-3286
@en
name
Ana P Berbegall
@ast
Ana P Berbegall
@en
Ana P Berbegall
@es
Ana P Berbegall
@nl
type
label
Ana P Berbegall
@ast
Ana P Berbegall
@en
Ana P Berbegall
@es
Ana P Berbegall
@nl
prefLabel
Ana P Berbegall
@ast
Ana P Berbegall
@en
Ana P Berbegall
@es
Ana P Berbegall
@nl
P21
P31
P496
0000-0002-8798-3286